ADC Therapeutics Presents Updates From ZYNLONTA LOTIS Clinical Trial Programs At SOHO 2023
Portfolio Pulse from Benzinga Newsdesk
ADC Therapeutics has presented updates from its ZYNLONTA LOTIS clinical trial programs at the SOHO 2023 event. The updates may have implications for the company's future performance.
August 31, 2023 | 6:10 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ADC Therapeutics' updates from its ZYNLONTA LOTIS clinical trial programs could potentially impact the company's stock performance.
The updates from ADC Therapeutics' ZYNLONTA LOTIS clinical trial programs could potentially influence investor sentiment and thus the company's stock performance. However, the exact impact will depend on the specifics of the updates, which are not detailed in the news.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100